ES2044087T3 - Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada. - Google Patents

Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada.

Info

Publication number
ES2044087T3
ES2044087T3 ES89301888T ES89301888T ES2044087T3 ES 2044087 T3 ES2044087 T3 ES 2044087T3 ES 89301888 T ES89301888 T ES 89301888T ES 89301888 T ES89301888 T ES 89301888T ES 2044087 T3 ES2044087 T3 ES 2044087T3
Authority
ES
Spain
Prior art keywords
dihydro
stabilized
composition
cetoprostaglandine
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89301888T
Other languages
English (en)
Inventor
Ryuji Ueno
Sachiko Kuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo KK filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Application granted granted Critical
Publication of ES2044087T3 publication Critical patent/ES2044087T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN COMPUESTO ESTABLE DE 13,14 - DIHIDRO - 15 - CETOPROSTAGLANDINA QUE TIENE UNA MEZCLA INTIMA DE A) UNA CANTIDAD EFECTIVA TERAPEUTICAMENTE DE AL MENOS UN COMPUESTO SELECCIONADO DE 13, 14 DIHIDRO - 15 - CETOPOROSFAGLANDINAS; Y B) AL MENOS UN COMPUESTO SELECCIONADO DE CICLODEXTRINAS ESTERIZADAS ACEPTABLES FARMACEUTICAMENTE.
ES89301888T 1988-02-26 1989-02-24 Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada. Expired - Lifetime ES2044087T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63045622A JP2597629B2 (ja) 1988-02-26 1988-02-26 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化

Publications (1)

Publication Number Publication Date
ES2044087T3 true ES2044087T3 (es) 1994-01-01

Family

ID=12724473

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89301888T Expired - Lifetime ES2044087T3 (es) 1988-02-26 1989-02-24 Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada.

Country Status (13)

Country Link
EP (1) EP0330511B1 (es)
JP (1) JP2597629B2 (es)
KR (1) KR970005170B1 (es)
AT (1) ATE79260T1 (es)
AU (1) AU612791B2 (es)
CA (1) CA1314483C (es)
DE (1) DE68902401T2 (es)
ES (1) ES2044087T3 (es)
GB (1) GB2216004A (es)
GR (1) GR3005933T3 (es)
NZ (1) NZ228111A (es)
OA (1) OA09236A (es)
ZA (1) ZA891410B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
ATE101342T1 (de) * 1988-09-06 1994-02-15 Kabi Pharmacia Ab Prostaglandinderivate zur behandlung des gruenen stars oder einer okularen hypertension.
ATE111736T1 (de) * 1988-10-01 1994-10-15 R Tech Ueno Ltd Okulare hypotensive mittel.
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
ATE122563T1 (de) * 1989-07-27 1995-06-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von 15-keto-prostansäure-derivaten zur herstellung eines medikaments für die verbesserung der ausscheidung des kaliumions.
CA2022372C (en) * 1989-08-09 2000-05-02 Ryuji Ueno Improvement of excretion of nonprotein nitrogen into the intestine by prostanoic acid derivatives
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
TW224942B (es) * 1990-04-04 1994-06-11 Adka Ueno Kk
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
DE69213057T2 (de) * 1991-03-14 1997-01-09 Ueno Seiyaku Oyo Kenkyujo Kk Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6169111B1 (en) 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
US6211226B1 (en) 1998-12-17 2001-04-03 Alcon Laboratories, Inc. 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
CA2502439C (en) 2002-10-23 2011-11-22 Sucampo Ag Prostaglandin compounds for the treatment of obesity
US20080139652A1 (en) 2003-11-07 2008-06-12 Yusuke Sakai Pharmaceutical Composition Containing Prostaglandin
EP1985298A1 (en) 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910525A (ja) * 1982-06-21 1984-01-20 Teisan Seiyaku Kk プロスタグランジンｅの安定化組成物
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
CA1323364C (en) 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (es) 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
ES2052735T3 (es) 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.

Also Published As

Publication number Publication date
GB2216004A (en) 1989-10-04
JP2597629B2 (ja) 1997-04-09
ZA891410B (en) 1989-11-29
EP0330511A3 (en) 1989-10-18
AU612791B2 (en) 1991-07-18
KR970005170B1 (en) 1997-04-14
ATE79260T1 (de) 1992-08-15
AU3029889A (en) 1989-08-31
DE68902401T2 (de) 1992-12-10
KR890012654A (ko) 1989-09-18
EP0330511A2 (en) 1989-08-30
OA09236A (en) 1992-06-30
JPH01221317A (ja) 1989-09-04
GR3005933T3 (es) 1993-06-07
EP0330511B1 (en) 1992-08-12
DE68902401D1 (de) 1992-09-17
GB8904232D0 (en) 1989-04-12
CA1314483C (en) 1993-03-16
NZ228111A (en) 1991-02-26

Similar Documents

Publication Publication Date Title
ES2044087T3 (es) Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada.
IL136249A0 (en) Suppository containing an acid-labile active compound
BR8901037A (pt) Compostos,mistura sensivel a luz e processo para a preparacao de um composto
LU90943I2 (fr) Kineret-anakinra et ses dérivés pharmaceutiquement acceptables
PL303937A1 (en) Application of an antiestrogen compound and pharmaceutical agent
NO855048L (no) Fremgangsmaate for fremstilling av et stabilisert nicorandil-preparat.
ES522107A0 (es) Procedimiento para preparar composiciones farmaceuticas inyectadas que contienen derivados de 2-metil-3-carboxamida-4-hidroxitiazina 1,1-dioxido.
JPS5753414A (en) Stabilized medicinal composition
DE69828043D1 (de) Fluoridfreie zahnremineralisierung
ATE78166T1 (de) Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
IT8348950A0 (it) Composizione farmaceutica a base di antibiotici beta-lattamici,procedimento per prepararla e metodo per stabilizzarla
MY104979A (en) [ 5(6)(ih-azole-1-ylmethyl) benzimidazole] carbamates.
IL105475A0 (en) Pharmaceutical compositions containing 1alpha,24(r)-dihydroxy-22(e)-dehydro-vitamin d3 for treating osteoporosis
ES2004097A6 (es) Procedimiento de preparacion de un nuevo derivado triciclico denominado acido 5-(3-cloro-6-metil-5,5-dioxo-6,11-dihidro-(c,f)-dibenzo-(1,2)-tiazepin-11-il)amino)-pentanoico
HU9202163D0 (en) New glyco-peptides, method for producing them and pharmaceutical preparatives containing these compounds
DE3766885D1 (en) Chlorpheniramine therapie.
NO178096C (no) Fremgangsmåte for fremstilling av et transdermalt leveringssystem for en farmasöytisk aktiv forbindelse
FI884838A (fi) Nytt s-timololderivat och foerfarande foer dess framstaellning.
SE8800461L (sv) Farmaceutisk komposition
ES2033247T3 (es) Metodo para preparar una composicion farmaceutica a base de un compuesto antraquinonico.
HUT49870A (en) Process for producing new 1,2-dithiolo-3-thion-s-oxide derivatives and pharmaceutical compositions comprising these compounds
IT1229178B (it) Procedimento per l'ottenimento di una miscela di ribonucleotidi.
ES545622A0 (es) Un procedimiento para preparar bisarilamidas de n,n'-di(1 aminoalquil-2) alquilendiaminas.
FI894813A (fi) Menetelmä terapeuttisesti aktiivisten 2-metoksikarbonyylisubstituoitujen N,N'-di(trimetoksibentsoyyli)piperatsiinijohdannaisten valmistamiseksi
IT8721890A0 (it) Composti amminici stericamente impediti e procedimento per la loro preparazione.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 330511

Country of ref document: ES